A recent study where empagliflozin was added to RAS inhibitors for 12 weeks in people with CKD with or without diabetes and albuminuria demonstrated a significant increase in angiotensin 1–7, angiotensin I levels and upregulation of plasma renin activity in people with the diabetes (27). This evidence concerns the gene AGT and diabetes mellitus.